Lantern Pharma Inc. Common Stock (NASDAQ:LTRN)

Home >> Stock >> Lantern Pharma Inc. Common Stock >> Statement

Blog+More

Federal Reserve delivers a second interest rate hike to 1.75%-2% and then expects more rate increases in late-2018.

Charlene Vos

2018-06-08 13:35:00 Friday ET

Federal Reserve delivers a second interest rate hike to 1.75%-2% and then expects more rate increases in late-2018.

The Federal Reserve delivers a second interest rate hike to 1.75%-2% and then expects subsequent rate increases in September and December 2018 to dampen inf

+See More

President Trump floats generous 10% tax cuts for the U.S. middle class ahead of the November 2018 mid-term elections.

Jacob Miramar

2018-10-21 14:40:00 Sunday ET

President Trump floats generous 10% tax cuts for the U.S. middle class ahead of the November 2018 mid-term elections.

President Trump floats generous 10% tax cuts for the U.S. middle class ahead of the November 2018 mid-term elections. Republican senators, congressmen, and

+See More

Response to USPTO fintech patent protection and accreditation

Andy Yeh Alpha

2023-01-09 10:31:00 Monday ET

Response to USPTO fintech patent protection and accreditation

Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent

+See More

We assess almost all aspects of the current global race toward artificial general intelligence (AGI) between both the U.S. and China.

Monica McNeil

2027-10-31 00:00:00 Sunday ET

We assess almost all aspects of the current global race toward artificial general intelligence (AGI) between both the U.S. and China.

In the technological race between the U.S. and China, America leads in some strategic sectors from AI large language models (LLM), graphics processing units

+See More

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

John Fourier

2024-05-05 10:31:00 Sunday ET

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

Stock Synopsis: Pharmaceutical post-pandemic patent development cycle In terms of stock market valuation, the major pharmaceutical sector remains at its

+See More

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

John Fourier

2018-03-11 08:27:00 Sunday ET

Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018 with an incredible rags-to-riches life story.

At 89 years old, Hong Kong billionaire Li Ka-Shing announces his retirement in March 2018. With a personal net worth of $35 billion, Li has an incredible ra

+See More